Evidence map›Paper›PMID 31288230›Full record

ReviewNephron2019

Role of Natural IgM and IgM Induced Bregs in Preventing Ischemia Induced Innate Inflammation and Acute Kidney Injury.

Peter I Lobo, Mark D Okusa

Open access · bronzeAbstract readReview
In one paragraph

Review in Nephron, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Peter I LoboDivision of Nephrology and CIIR, University of Virginia Health System, Charlottesville, Virginia, USA, PIL@hscmail.mcc.virginia.edu.
Mark D OkusaDivision of Nephrology and CIIR, University of Virginia Health System, Charlottesville, Virginia, USA.
University of Virginia Health System · US

Funding

UAB-UCSD O'Brien Core Center for Acute Kidney Injury ResearchP30DK079337 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AGARWAL, ANUPAM · 2008 to 2022
$18.3M
Naturally Occurring IgM Anti-Leucocyte Autoantibodies Protect Against Renal IRIR01DK083406 · NIDDK · UNIVERSITY OF VIRGINIA · PI LOBO, PETER, OKUSA, MARK DOUGLAS · 2010 to 2014
$2.1M
CpG and B cells, pretreated ex-vivo with natural IgM, protect against renal IRIR01DK114366 · NIDDK · UNIVERSITY OF VIRGINIA · PI LOBO, PETER · 2018 to 2021
$1.5M
NIDDK NIH HHS P30 DK079337NIDDK NIH HHS R01 DK083406NIDDK NIH HHS R01 DK114366
6 · The paper itself

Abstract

Ischemic acute kidney injury (AKI) is predominantly mediated by the innate inflammatory response to damage-associated molecular patterns released during the reperfusion phase of the ischemic event. In this study, we show that pre-emptive IgM infusions to increase binding of natural IgM (nIgM) anti-leucocyte autoantibodies (IgM-ALA), inhibit this inflammatory response and prevent AKI in mice. Similarly, AKI was prevented by pre-emptively infusing Bregs, induced ex vivo by pre-treating pan-B cells with nIgM. Harnessing such a physiologic mechanism to inhibit inflammation and prevent ischemia-induced AKI can have translational potential in humans. For example, one can pre-emptively infuse IgM or ex vivo induced Bregs in patients who have a high risk of developing ischemia-induced AKI, especially the subset of these patients with low levels of IgM-ALA or regulatory T cells (Tregs).

Indexed as

Acute Kidney InjuryAnimalsAutoantibodiesB-Lymphocytes, RegulatoryHumansImmunity, InnateImmunoglobulin MInflammationIschemiaKidneyAutoantibodiesImmunoglobulin MAcute renal injuryInflammationNatural IgM

Identifiers

PMID31288230
PMCPMC6821571
OpenAlexW2960969871

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.